{"product_id":"evgn-ansoff-analysis","title":"(EVGN) Evogene Ltd. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Evogene Ltd. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification in one concise framework. This page includes a real preview\/sample of the analysis so you can review style and substance before buying; purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCPB-led co-development with BASF, Corteva and Bayer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene’s CPB-led co-development with BASF SE, Corteva and Bayer is a clear market penetration play: it uses existing licensing ties to push Evogene’s Computational Predictive Biology into current seed and crop-protection channels. With three global ag leaders already in the network, Evogene can widen adoption without building a new sales stack. The logic is simple: sell deeper into markets already served.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePriority crop concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. focuses on corn, soybean, wheat, rice, and cotton, five crops that dominate global acreage and spending; USDA data puts 2025-26 world corn output near 1.3 billion metric tons and soybean output near 420 million tons. That scale supports market penetration because demand is already deep. Its seed trait, crop chemical, and biological programs fit these same large segments, so each win can scale fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-division platform leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene’s 3 divisions—Agriculture, Human Health, and Industrial Applications—can use 1 CPB discovery platform to reach more buyers inside current markets. That raises cross-selling chances and lowers the cost of serving each segment because the same engine supports multiple customer needs. In market penetration terms, one platform can deepen share without building a new stack for every division.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS, Israel and Brazil operating base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd. has a three-country operating base in the US, Israel, and Brazil, which makes market penetration a near-term play in familiar geographies. The main upside is deeper commercialization and more partner-led activity in these same markets, rather than a new-country push. Its wider international footprint also gives it more room for local execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 core operating countries\u003c\/li\u003e\n\u003cli\u003eFocus on deeper commercialization\u003c\/li\u003e\n\u003cli\u003ePartner activity can scale faster\u003c\/li\u003e\n\u003cli\u003eOther markets widen execution options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCanonic-Cannbit medical cannabis channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCanonic Ltd. and Cannbit Ltd. give Evogene Ltd. a direct medical cannabis route in an existing product line, so this is market penetration, not a new-category push. It deepens reach in a regulated niche where Cannbit already sells, which can lift usage without building a new channel from scratch.\u003c\/p\u003e\n\u003cp\u003eFor Evogene Ltd., the value is faster access, lower go-to-market friction, and more repeat demand in medical cannabis. The partnership is a channel play that can widen patient uptake and strengthen share in the same market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting cannabis line, not new category\u003c\/li\u003e\n\u003cli\u003eDirect route to medical users\u003c\/li\u003e\n\u003cli\u003eLower channel-build cost\u003c\/li\u003e\n\u003cli\u003eStronger share in same market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene Expands Fast in Major Crops with BASF, Corteva, and Bayer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s market penetration is driven by deeper use of its CPB platform with BASF SE, Corteva, and Bayer in existing seed and crop-protection channels. With 2025-26 world corn output near 1.3 billion metric tons and soybeans near 420 million tons, its focus on major crops can scale fast. The goal is simple: win more share in markets it already serves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore crops\u003c\/td\u003e\n\u003ctd\u003ecorn, soybean, wheat, rice, cotton\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor 2025-26 output\u003c\/td\u003e\n\u003ctd\u003ecorn 1.3bn tons; soybeans 420m tons\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey partners\u003c\/td\u003e\n\u003ctd\u003eBASF SE, Corteva, Bayer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Evogene Ltd.’s growth strategy through market and product expansion options in the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear, at-a-glance Ansoff Matrix for Evogene Ltd. to speed growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography linking each Ansoff growth path for Evogene Ltd. to primary, credible sources for fast verification and defensible decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational rollout beyond core geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. already operates in the United States, Israel and Brazil, so international rollout is a fit for its existing global model. Extending its CPB-based solutions into new countries can reuse the same platform, partners and field-validation work, which lowers launch risk. For market development, the key test is whether new regions can match the adoption seen in Evogene Ltd.'s current markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural expansion into new crop markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s agriculture pipeline already spans 5 major crops: corn, soybean, wheat, rice and cotton. That makes market development a practical Ansoff move, because the same product concepts can be pushed into new crop geographies without redesigning the core platform. With global crop demand still broad and fragmented, even one validated trait or biological can scale across multiple farming regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led entry into new regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. uses partner-led entry to reach new regions through BASF, Corteva and Bayer, three firms that already sell across global farm markets. BASF Crop Protection booked about €9.8 billion in 2024 sales, Corteva about $17.4 billion, and Bayer Crop Science about €22.3 billion, so their channels can open markets Evogene has not built on its own. Distribution and licensing are the clearest path for faster regional access and lower launch risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHuman health programs for broader territories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd. can use market development to take its human health programs in immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections into new countries and care systems without changing the core science. The case is strong: cancer caused about 9.7 million deaths in 2022, and antimicrobial resistance was linked to 1.27 million deaths in 2019.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame pipeline, new geographies.\u003c\/li\u003e\n\u003cli\u003eFits oncology, GI, and AMR demand.\u003c\/li\u003e\n\u003cli\u003eScale via local trials and partners.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat route can raise addressable patients while keeping R\u0026amp;D focused on one therapeutic set.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIndustrial raw-material applications abroad\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd.’s industrial raw-materials work uses castor bean seed enhancement to lift yield and quality, and castor seed typically contains about 45% to 55% oil. That lets the same platform target new buyers in chemicals, lubricants, and bio-based inputs beyond current core locations, widening addressable demand for castor-based raw materials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigher seed oil content supports scale.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eOne platform can serve multiple markets.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eGeographic reach can expand demand.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene’s Same Platform, Bigger Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. can grow by taking its existing crop and health platforms into new countries, using the same science, partners and validation work. Partner channels matter: Bayer Crop Science posted about €22.3 billion in 2024 sales, Corteva about $17.4 billion, and BASF Crop Protection about €9.8 billion. Same platform, wider reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eMarket role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop partners\u003c\/td\u003e\n\u003ctd\u003e€22.3bn, $17.4bn, €9.8bn\u003c\/td\u003e\n\u003ctd\u003eFast regional access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman health\u003c\/td\u003e\n\u003ctd\u003e9.7m cancer deaths; 1.27m AMR deaths\u003c\/td\u003e\n\u003ctd\u003eNew patient markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCastor oil\u003c\/td\u003e\n\u003ctd\u003e45%-55% oil\u003c\/td\u003e\n\u003ctd\u003eNew industrial buyers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eEvogene Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable Ansoff Matrix for Evogene Ltd., ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew seed traits pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. uses its agriculture division to push new seed traits for the same crop customers, so this is classic product development in the Ansoff Matrix. The CPB discovery platform helps screen and refine trait candidates faster, which matters because trait R\u0026amp;D can take years and many programs fail before field validation. This path can lift share in existing markets without needing a new crop base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAg-chemical and biological product creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd. uses its digital discovery platform to create new ag-chemical and biological crop inputs for existing farm markets, which is classic product development in the Ansoff Matrix. The crop protection and biologicals market keeps expanding, with biological crop protection projected to reach about $20 billion by 2027, so new products can tap real demand without changing the customer base. This fits Evogene’s model: design, screen, and guide new life-science products faster and with lower lab-to-field risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrobiome-based treatment pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s human health unit is extending its current pipeline into human microbiome-based treatments, with new products aimed at immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. This is a direct fit with its existing health focus, so it raises adjacency without needing a new business model. The microbiome field is already in clinical development, with programs spanning Phase 2 and Phase 3, which supports the case for faster pipeline reuse.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCastor bean seed enhancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene’s castor bean seed enhancement fits product development: it upgrades an existing raw material line with better seed traits for industrial users. Castor seeds typically contain about 45% to 55% oil, so even small yield or quality gains can lift downstream value. In 2025, Evogene kept this as a focused innovation lane inside its industrial biotech work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting market, new seed offer\u003c\/li\u003e\n\u003cli\u003eTargets industrial-grade quality\u003c\/li\u003e\n\u003cli\u003eHigh oil content supports upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical cannabis offerings through Canonic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene Ltd.'s medical cannabis work through Canonic Ltd. and its Cannbit Ltd. tie-up is a product development move in the Ansoff Matrix: new products, same medical-use market. That fits a low-friction expansion path because it builds on channels the Company already serves.\u003c\/p\u003e\n\u003cp\u003eFor FY2025, the most decision-useful read is whether Canonic’s product pipeline can raise share in existing medical cannabis demand without needing a new market build.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, new medical products\u003c\/li\u003e\n\u003cli\u003eUses Canonic and Cannbit access\u003c\/li\u003e\n\u003cli\u003eLimits go-to-market risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene Expands Products, Not Markets, to Cut Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s product development play is clear in FY2025: it keeps the same ag and health markets, but adds new traits, biologicals, and microbiome products. That fits the Ansoff Matrix, and it lowers market-entry risk because the customer base is already there.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 lane\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eAg and health\u003c\/td\u003e\n\u003ctd\u003eNew products for existing users\u003c\/td\u003e\n\u003ctd\u003eRaises share without new market build\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgriculture to human health expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene’s move from crop discovery into human health is classic diversification: it now serves two very different markets, with the same CPB engine powering both. That shared platform lowers retooling risk, while the shift from agriculture to therapeutic development widens its addressable market and reduces reliance on crop-cycle demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrobiome therapeutics in oncology GI and AMR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.'s human health arm is a clear diversification move: it extends beyond agriculture into microbiome therapeutics for oncology, gastrointestinal disease, and antimicrobial-resistant infections. That shifts the company into new patient markets and product types, where global AMR alone is linked to about 1.27 million deaths each year. It also broadens revenue options beyond seed and crop tech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial castor bean platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvogene’s industrial castor bean platform is a clear diversification move in Ansoff terms: it opens a non-agricultural, non-human-health line with a separate customer base. Castor bean seed enhancement targets industrial raw-material demand, and more than 90% of castor output already goes to industrial uses, not food. That gives Evogene exposure to a distinct end market with different pricing and demand drivers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical cannabis via Canonic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene’s medical cannabis work through Canonic Ltd. and Cannbit Ltd. adds an adjacent market to its core crop-trait and microbiome focus. That moves the company from one life-science lane into a broader mix of seed-tech, microbial, and cannabis product work. In Ansoff terms, this is diversification: new products in a new or lightly related market.\u003c\/p\u003e\n\u003cp\u003eIt can spread revenue risk, but it also raises execution and regulatory risk. The bigger point is simple: Evogene is widening its business mix beyond core ag-tech.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjacent market added: medical cannabis\u003c\/li\u003e\n\u003cli\u003eSubsidiaries: Canonic Ltd., Cannbit Ltd.\u003c\/li\u003e\n\u003cli\u003eStrategy: diversification in Ansoff Matrix\u003c\/li\u003e\n\u003cli\u003eEffect: broader life-science exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMicrobes small molecules and genetic components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvogene’s CPB platform diversifies the company by sourcing solutions from microbes, small molecules, and genetic components, so one discovery engine can feed several life-science markets. That breadth matters because it spreads R\u0026amp;D risk across product types and lets Evogene pursue ag-biologicals, human health, and other adjacent uses from one core platform. This is the main diversification lever in the portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne platform, multiple product classes\u003c\/li\u003e\n\u003cli\u003eSupports cross-market expansion\u003c\/li\u003e\n\u003cli\u003eReduces single-asset dependence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvogene’s One Engine Powers Multiple Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvogene Ltd.’s diversification is real: it uses its CPB platform across ag-biologicals, human health, castor, and cannabis, so one engine feeds several end markets. That lowers dependence on crop cycles, but it also raises execution and regulatory risk. The clearest proof is the move into human health and cannabis, both outside core ag-tech.\u003c\/p\u003e\n\u003cp\u003eGlobal AMR is linked to about 1.27 million deaths a year, and more than 90% of castor output goes to industrial uses, not food.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman health\u003c\/td\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003ctd\u003eAMR deaths: 1.27m\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCastor\u003c\/td\u003e\n\u003ctd\u003eIndustrial end market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% industrial use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234317082889,"sku":"evgn-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/evgn-ansoff-matrix.webp?v=1785718196","url":"https:\/\/dcfanalyst.com\/products\/evgn-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}